Literature DB >> 21896144

β-Adrenergic blockers.

William H Frishman1, Elijah Saunders.   

Abstract

KEY POINTS AND PRACTICAL RECOMMENDATIONS: •  β-Blockers are appropriate treatment for patients with hypertension and those who have concomitant ischemic heart disease, heart failure, obstructive cardiomyopathy, or certain arrhythmias. •  β-Blockers can be used in combination with other antihypertensive drugs to achieve maximal blood pressure control. Labetalol can be used in hypertensive emergencies and urgencies. •  β-Blockers may be useful in patients having hyperkinetic circulation (palpitations, tachycardia, hypertension, and anxiety), migraine headache, and essential tremor. •  β-Blockers are highly heterogeneous with respect to various pharmacologic effects: degree of intrinsic sympathomimetic activity, membrane-stabilizing activity, β(1) selectivity, α(1) -adrenergic-blocking effect, tissue solubility, routes of systemic elimination, potencies and duration of action, and specific effects may be important in the selection of a drug for clinical use. •  β-Blocker usage to reduce perioperative ischemia and cardiovascular complications may not benefit as many patients as was once hoped and may actually cause harm in some individuals. Currently the best evidence supports β-blocker use in two patient groups: patients undergoing vascular surgery with known ischemic heart disease or multiple risk factors for it and for patients already receiving β-blockers for known cardiovascular conditions.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21896144      PMCID: PMC8108946          DOI: 10.1111/j.1751-7176.2011.00515.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  37 in total

1.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.

Authors:  Björn Dahlöf; Peter S Sever; Neil R Poulter; Hans Wedel; D Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2005 Sep 10-16       Impact factor: 79.321

2.  Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis.

Authors:  Nadia Khan; Finlay A McAlister
Journal:  CMAJ       Date:  2006-06-06       Impact factor: 8.262

Review 3.  Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis.

Authors:  Lars Hjalmar Lindholm; Bo Carlberg; Ola Samuelsson
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

4.  Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.

Authors:  Bryan Williams; Peter S Lacy; Simon M Thom; Kennedy Cruickshank; Alice Stanton; David Collier; Alun D Hughes; H Thurston; Michael O'Rourke
Journal:  Circulation       Date:  2006-02-13       Impact factor: 29.690

5.  Fifty years of beta-adrenergic blockade: a golden era in clinical medicine and molecular pharmacology.

Authors:  William H Frishman
Journal:  Am J Med       Date:  2008-11       Impact factor: 4.965

Review 6.  Making health care safer: a critical analysis of patient safety practices.

Authors:  K G Shojania; B W Duncan; K M McDonald; R M Wachter; A J Markowitz
Journal:  Evid Rep Technol Assess (Summ)       Date:  2001

7.  Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document.

Authors:  Giuseppe Mancia; Stéphane Laurent; Enrico Agabiti-Rosei; Ettore Ambrosioni; Michel Burnier; Mark J Caulfield; Renata Cifkova; Denis Clément; Antonio Coca; Anna Dominiczak; Serap Erdine; Robert Fagard; Csaba Farsang; Guido Grassi; Hermann Haller; Anthony Heagerty; Sverre E Kjeldsen; Wolfgang Kiowski; Jean Michel Mallion; Athanasios Manolis; Krzysztof Narkiewicz; Peter Nilsson; Michael H Olsen; Karl Heinz Rahn; Josep Redon; José Rodicio; Luis Ruilope; Roland E Schmieder; Harry A J Struijker-Boudier; Pieter A van Zwieten; Margus Viigimaa; Alberto Zanchetti
Journal:  J Hypertens       Date:  2009-11       Impact factor: 4.844

8.  USE OF PROPRANOLOL (INDERAL) IN TREATMENT OF HYPERTENSION.

Authors:  B N PRICHARD; P M GILLAM
Journal:  Br Med J       Date:  1964-09-19

Review 9.  beta-Adrenergic blockers: a 50-year historical perspective.

Authors:  William H Frishman
Journal:  Am J Ther       Date:  2008 Nov-Dec       Impact factor: 2.688

10.  MRC trial of treatment in elderly hypertensives.

Authors:  A F Lever; P J Brennan
Journal:  Clin Exp Hypertens       Date:  1993-11       Impact factor: 1.749

View more
  22 in total

Review 1.  Pharmacology of myocardial calcium-handling.

Authors:  Julia Vogler; Lars Eckardt
Journal:  Wien Med Wochenschr       Date:  2012-06-16

Review 2.  A Comparison of Vasodilating and Non-vasodilating Beta-Blockers and Their Effects on Cardiometabolic Risk.

Authors:  Icilma V Fergus; Kenneth L Connell; Keith C Ferdinand
Journal:  Curr Cardiol Rep       Date:  2015-06       Impact factor: 2.931

3.  CYP2C19 genotype has a major influence on labetalol pharmacokinetics in healthy male Chinese subjects.

Authors:  Sze Wa Chan; Miao Hu; Sara Shun Wah Ko; Catherine Wing Yan Tam; Benny Siu Pong Fok; Ophelia Qi Ping Yin; Moses Sing Sum Chow; Brian Tomlinson
Journal:  Eur J Clin Pharmacol       Date:  2012-10-23       Impact factor: 2.953

Review 4.  The immune system and hypertension.

Authors:  Madhu V Singh; Mark W Chapleau; Sailesh C Harwani; Francois M Abboud
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

Review 5.  Therapies to Reduce Blood Pressure Acutely.

Authors:  Joseph B Miller; Harish Kinni; Ahmed Amer; Phillip D Levy
Journal:  Curr Hypertens Rep       Date:  2016-06       Impact factor: 5.369

Review 6.  New Insight into Effects of β-Blockers on Arterial Functions.

Authors:  Kazuo Eguchi
Journal:  Pulse (Basel)       Date:  2016-01-20

Review 7.  β-Adrenergic modulation of cancer cell proliferation: available evidence and clinical perspectives.

Authors:  Marisa Coelho; Cátia Soares-Silva; Daniela Brandão; Franca Marino; Marco Cosentino; Laura Ribeiro
Journal:  J Cancer Res Clin Oncol       Date:  2016-10-05       Impact factor: 4.553

8.  Chemogenetic and Optogenetic Activation of Gαs Signaling in the Basolateral Amygdala Induces Acute and Social Anxiety-Like States.

Authors:  Edward R Siuda; Ream Al-Hasani; Jordan G McCall; Dionnet L Bhatti; Michael R Bruchas
Journal:  Neuropsychopharmacology       Date:  2016-01-04       Impact factor: 7.853

9.  Development of a sustained-release microcapsule for delivery of metoprolol succinate.

Authors:  Li Song; Shengjiang He; Qineng Ping
Journal:  Exp Ther Med       Date:  2017-03-21       Impact factor: 2.447

10.  Beta-adrenergic stimulation maintains cardiac function in Serca2 knockout mice.

Authors:  Sander Land; William E Louch; Steven A Niederer; Jan Magnus Aronsen; Geir Christensen; Ivar Sjaastad; Ole M Sejersted; Nicolas P Smith
Journal:  Biophys J       Date:  2013-03-19       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.